StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Free Report) in a report released on Saturday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright reiterated a neutral rating on shares of TRACON Pharmaceuticals in a research note on Monday, July 1st.
Check Out Our Latest Research Report on TCON
TRACON Pharmaceuticals Price Performance
TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter. The business had revenue of $0.06 million during the quarter.
TRACON Pharmaceuticals Dividend Announcement
The firm also recently declared a dividend, which was paid on Monday, July 8th. Stockholders of record on Friday, June 28th were paid a $0.045 dividend. The ex-dividend date was Thursday, June 27th. This represents a dividend yield of 40.3%.
About TRACON Pharmaceuticals
TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.
Further Reading
- Five stocks we like better than TRACON Pharmaceuticals
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- 2 Option Strategies to Maximize Profits in a Bear Market
- How is Compound Interest Calculated?
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.